Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Entities / ODM-212
Other

ODM-212

Tracked across 1 events · 6 articles · First seen May 21, 2026 · Last active May 30, 2026

Sentiment
65
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 65
Tech
Orion Pharma Presents ODM-212 Trial Data
Orion announced the first clinical data from its Phase 1/2 TEADES trial for ODM-212, an investigational oral pan-TEAD inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting. The results indicated that ODM-212 was…
Impact: ODM-212 is an investigational oral small-molecule pan-TEAD inhibitor developed by Orion, showing early efficacy in treating advanced solid tumors, particularly mesothelioma and EHE.
May 21, 2026 · 6 articles
Key Actions (2)
95 ODM-212 showed early efficacyOrion Pharma Presents...
90 Orion developed ODM-212Orion Pharma Presents...
NEWSDESK
Track ODM-212 live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.